Background and purpose: Long-term adaptations to pharmacological stimuli frequently originate from modulation of complex intracellular signalling pathways. We previously reported that HU210 and CP55940, two CB 1 cannabinoid receptor agonists, induced opposite effects on TH expression. Herein, we characterized their influence on cAMP response element (CRE) and activator protein 1 (AP-1)-mediated regulation of gene transcription. Experimental approach: The activity of the agonists was examined on transfected N1E-115 cells in which expression of the luciferase reporter gene was controlled by transcription promoters consisting of repeats of either CRE or AP-1 elements. In addition, the implication of classical signalling pathways was investigated using a variety of kinase inhibitors. Key results: Consistent with the CB 1 -mediated reduction of cAMP accumulation, both ligands decreased CRE-driven luciferase expression with similar potencies. HU210 also exhibited a concentration-dependent reduction of luciferase activity in cells engineered to examine AP-1-controlled transcription, whereas such response was not obtained with CP55940. Responses were all inhibited by SR141716A and were modified in Pertussis toxin-treated cells, suggesting agonist-selective regulations of distinct G i/o -dependent mechanisms through CB 1 receptor activation. Finally, PKC inhibitors efficiently inhibited the paradoxical effect of HU210 on AP-1-mediated transcription, indicating selective regulation of PKC-dependent responses.
Introduction
Besides radioligand-binding studies, pharmacological characterization of synthetic drugs acting at G-protein-coupled receptors consists of the study of their potency and intrinsic activity in functional assays. Considering the signalling pathways activated by these receptors, these assays are generally focused on the measure of conventional immediate and transient responses, such as production of second messengers, activation of kinases or alteration in ion equilibriums. Although these acute responses provide relevant details regarding the pharmacodynamic properties of the ligand, it is well documented that delayed or long-term modulations of cell functions contribute to the clinical outcome obtained with these ligands.
With respect to cannabinoids that are classically documented to signal through inhibition of adenylyl cyclase (AC), several reports indicate that activation of cannabinoid receptors leads to the regulation of several DNA-binding proteins, including activator protein 1 (AP-1) (Porcella et al., 1998) and cAMP response element-binding protein (CREB) (Herring et al., 1998) . Little is presently known regarding the nature of cannabinoid-mediated cell signals putatively involved in these delayed responses. Hence, paradoxical results were sometimes observed regarding agonist-mediated alteration of second messenger production and modulation of transcriptional activity. Thus, 2-arachidonoylglycerol was shown to enhance cell transformation and carcinogenesis through the induction of AP-1 DNA binding (Zhao et al., 2005) , whereas D 9 -tetrahydrocannabinol reduced interleukin-2 transcription through a decrease in nuclear factors binding to the AP-1 site of the interleukin-2 promoter (Condie et al., 1996; Faubert and Kaminski, 2000) .
Apart from inhibition of AC via a Pertussis toxin (PTx)-sensitive G i/o protein (Pertwee, 1999; Alexander et al., 2008) , cannabinoid-induced accumulation of cAMP has also been reported (Glass and Felder, 1997) . This response is likely to reflect a functional coupling with G s -type G proteins, as it is preserved in recombinant (Bonhaus et al., 1998; Calandra et al., 1999) and native (Maneuf and Brotchie, 1997; Bash et al., 2003) systems after Ga i inactivation by PTx. Even more convincing are studies showing the functional switch of CB 1 receptor coupling from Ga i to Ga s following the sequestration of G i/o G-protein pool through dopamine D 2 receptor coactivation (Glass and Felder, 1997) or overexpression (Jarrahian et al., 2004) . In addition, both CB 1 and CB 2 receptors were reported to stimulate ERK1/2 (extracellularsignal regulated kinase) (Bouaboula et al., 1995) in a G i/o -dependent manner, through the Gbg subunit. The complexity of the intracellular signalling associated with the CB 1 receptor extends to the activation of members of the mitogen-activated protein kinases (MAPK), including c-Jun N-terminal kinase and p38 MAPK (Rueda et al., 2000) and the modulation of calcium and potassium currents (Mackie and Hille, 1992; Mackie et al., 1995) . In addition, CB 1 receptors may induce rapid and transient elevations of intracellular free Ca 2 þ concentrations through Gbg-mediated activation of PLCb (Sugiura et al., 1997) . Finally, regulation of PLC by CB 1 receptors was proposed to require coupling with different a-subunits of the G q/11 family (Ho et al., 1999) . Hence, the selective coupling to G q/11 protein in an agonistspecific manner was more recently demonstrated (Lauckner et al., 2005; McIntosh et al., 2007) . We recently reported cannabinoid-mediated regulation of tyrosine hydroxylase (TH) expression in the N1E-115 neuroblastoma cell line constitutively and selectively expressing the CB 1 receptor subtype. Particularly, different classes of full CB 1 agonists, belonging to different chemical families, were shown to induce opposite effects , raising the question of functional selectivity at the CB 1 receptor. In this context, the present study aims at further investigating CB 1 receptor-mediated signalling pathways involved in the regulation of gene expression. In view of the essential roles of both CRE and AP-1 cis-enhancer elements in constitutive and induced TH gene expression, CRE-or AP-1-driven luciferase reporter gene assays were carried out to elucidate the CB 1 receptor-mediated, agonist selective regulation of signalling pathways involved in longterm control of gene transcription.
Methods

Cell culture
All cell culture media and supplements were obtained from Invitrogen (Merelbeke, Belgium). Mouse neuroblastoma N1E-115 cells were grown in Dulbecco's MEM/NUT mix F-12 medium supplemented with 10% foetal calf serum, 100 UI mL À1 penicillin, 100 mg mL À1 streptomycin and 2 mM L-glutamine. All drug treatments were conducted in the same culture medium. At confluence, cells were trypsinized for dilutions. Cells were cultured at 37 1C in an atmosphere of humidified air and 5% CO 2 .
cAMP assay N1E-115 cells were seeded in 96-well plates (10 4 cells per well), 24 h before cannabinoid treatments. Cells were pretreated for 30 min with 0.1 mM IBMX (3-isobutyl-1-methylxanthine). Then, cannabinoid agonists were added for another 30 min incubation treatment in the absence or presence of 1 mM forskolin.
were used, cells were pretreated for 5 min with the cannabinoid inverse agonists/antagonists at 1 mM before the addition of the cannabinoid agonist. Where indicated, cells were treated overnight with 100 ng mL À1 PTx. cAMP levels were measured using cAMP Biotrak enzyme immunoassay system (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), according to the protocol provided by the manufacturer. Cells were incubated at 37 1C.
Plasmids, transfection and dual luciferase assay pCRE-Luc and pAP-1-Luc plasmids were purchased from Stratagene (La Jolla, CA, USA) and included 4 and 7 copies of CRE and AP-1 cis-enhancer elements, respectively, fused to the firefly luciferase gene. pRL 138 obtained from Dr E Pierreux (UCL, ICP, Brussels, Belgium) was used as an internal control to normalize for transfection variability. pRL 138 was constructed by the introduction of a 225 bp sequence of the PFK-2 promoter in the pRL null vector from Promega (Mannheim, Germany) encoding for Renilla luciferase, as described previously (Pierreux et al., 1998) . Cells were plated at a density of 10 5 cells per well in 24-well plates. Culture medium was changed after 24 h, and the cells were co-transfected with a reporter plasmid (3 mg per well and 5 mg per well for pCRE-Luc and pAP-1-Luc, respectively) and the pRL 138 plasmid at 0.25 mg per well. Transfection was performed overnight using the calcium phosphate co-precipitation method. After transfection, cells were washed three times with PBS buffer (137 mM NaCl, Drugs, chemical reagents and other materials (6,R)-trans-3-(1,1-dimethylheptyl)-6,7,10,10,-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo(b,d)pyran-9-methanol (HU210) and (1R,3R,4R)-3-(2-hydroxy-4-(1,1-dimethylheptyl) phenyl)-4-(3-hydroxypropyl)cyclohexan-1-ol (CP55940) were purchased from Tocris Cookson (Bristol, UK). The CB 1 receptor inverse agonist/antagonist, SR141716A, and the CB 2 receptor inverse agonist/antagonist, SR144528, were generously provided by Dr Barth and Dr Mossé, respectively (SanofiSynthélabo Research, Montpellier, France). Forskolin, IBMX, phorbol 12-myristate 13-acetate and PTx were purchased from Sigma (Boornem, Belgium). Stock solutions of drugs were prepared in dimethyl sulphoxide at 0.01 M and stored in aliquots at À80 1C. The final dimethyl sulphoxide concentration never exceeded 0.1%, which had no significant effect on assays.
Results
Modulation of cAMP accumulation
In agreement with several studies indicating the functional coupling of the cannabinoid receptors with G i/o proteins, both HU210 (0.1 mM) and CP55940 (0.1 mM), two typical cannabinoid full agonists, elicited a significant reduction in cAMP accumulation in N1E-115 neuroblastoma cells (21.8 and 36.5% reduction relative to control cells, respectively) ( Figure 1a ). To facilitate the detection of G i/o -mediated responses, basal AC activity was enhanced by the addition of 1 mM forskolin (leading to a robust 725 ± 56% induction of cAMP accumulation, relative to control). At the tested concentration, maximal response to forskolin is certainly not reached, as the EC 50 value of forskolin in mediating cAMP accumulation in N1E-115 cells is close to 10 mM (Stenstrom et al., 1985; Murphy and Byczko, 1989) . In these conditions, both HU210 and CP55940 exhibited a more pronounced inhibition of cAMP formation (50.9 and 56.0% reduction relative to forskolin treated cells, respectively) ( Figure 1b ). Confirming the specific involvement of CB 1 receptors, these responses were totally prevented by SR141716A, a selective CB 1 inverse agonist/antagonist, whereas SR144528, a selective CB 2 inverse agonist/antagonist, had no influence on the agonist-mediated reduction of cAMP levels (data not shown). Although basal cAMP level was significantly decreased in PTx-treated cells, HU210 (0.1 mM) and CP55940 (0.1 mM) elicited a significant increase in cAMP synthesis either in the absence ( Cannabinoid-mediated regulation of CRE and AP-1-dependent transcriptional activity To examine the effects of CB 1 receptor activation on CRE and AP-1-dependent transcriptional activities, N1E-115 cells were transiently transfected with plasmid constructs containing the luciferase gene under the control of cis-enhancer element repeats of either CRE (pCRE-Luc) or AP-1 (pAP-1-Luc). As expected, cells transfected with pCRE-Luc constructs displayed a robust basal luciferase activity (not shown), confirming a constitutive activity of CRE-dependent transcription in N1E-115 cells. In addition, the strong increase in luciferase activity (up to 850%) observed with forskolin 1 mM confirmed that the luciferase reporter gene is a reliable indicator of cAMP levels in this model. Both HU210 and CP55940 were found to modestly inhibit CRE-mediated transcriptional activity (estimated pEC 50 values of 7.21 ± 0.01 and 6.82 ± 0.09, respectively) ( Figure 2a ). More convincingly, when the agonists were tested in cells exposed to forskolin, both markedly reduced luciferase expression in a concentration-dependent manner, with pEC 50 values of 7.60 ± 0.01 and 8.07 ± 0.04 for HU210 and CP55940, respectively. In this assay, the analysis of concentration-response curves indicated Hill slopes distinct from unity (0.47 ± 0.04 and 0.41 ± 0.02 for HU210 and CP55940, respectively). Nevertheless, the responses to both agonists were markedly impaired using SR141716A (Figure 2b ), suggesting that inhibition of CRE activity was specifically driven through CB 1 receptor-dependent signalling pathways. Experiments were repeated in cells engineered to examine AP-1-controlled luciferase activity. As with the CRE construct, a noticeable constitutive AP-1-driven luciferase activity was detected. The efficiency of this system was validated using 0.08 mM phorbol 12-myristate 13-acetate, a PKC activator known to regulate AP-1 transcription, which produced a modest but significant increase in luciferase activity (124.8±2.4%, relative to control; Po0.01). In this assay, HU210 elicited a concentration-dependent reduction of AP-1 activity (pEC 50 of 7.95±0.11) (Figure 3a ) and experimental data best fitted with a standard sigmoidal curve (Hill slope close to 1). Again, SR141716A abolished the HU210-mediated response (Figure 3b) , confirming that the regulation of AP-1-dependent transcription was operating through CB 1 receptor activation.
Surprisingly, no significant influence on AP-1 activity was observed using CP55940, indicating that this commonly used agonist of the CB 1 receptor behaves as a neutral ligand on the cell-signalling pathway regulating AP-1-dependent transcriptional activity. The pharmacological profile of CP55940 was further examined by analysing its ability to antagonize cannabinoid-mediated regulation of AP-1 activity. As shown in Figure 4 , CP55940 caused a concentrationdependent rightward shift of the sigmoidal curve for HU210-induced luciferase activation. This clearly identifies CP55940 as a competitive antagonist at the CB 1 receptor in this functional assay and Schild plot transformation indicated a pA 2 value of 8.48 (95% confidence interval of 8. 22-8.92 ).
Signalling pathways involved in CRE and AP-1-dependent transcriptional activity The cellular mechanisms involved in the regulation of CRE and AP-1-dependent transcriptional activity by cannabinoid agonists were examined using inhibitors of intracellular signalling cascades putatively associated with CB 1 receptor functions. As this receptor appears predominantly associated with modulation of cAMP levels, we first studied the effect of the PKA inhibitors, H89 and KT5720, on both CRE and 
CP55940
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Figure 2 Cannabinoid-mediated regulation of CRE-dependent transcriptional activity in N1E-115 neuroblastoma cells. Luciferase activity was measured in transiently transfected N1E-115 cells carrying the pCRE-Luc construct. Cells were exposed to increasing concentrations of HU210 or CP55940 in the absence or presence of 1 mM forskolin (a) and luciferase activity was monitored 5 h later. The responses to both agonists (used at 0.1 mM) were also measured in the presence of 1 mM SR141716A (b). The role of G i/o -type G proteins was investigated by repeating these measures in the presence of forskolin on cells treated overnight with PTx (100 ng mL À1 ) (c). Results (mean values with s.e.mean from at least three separate experiments performed in triplicate) are given as the percentages of relative luciferase activity (firefly luciferase relative to Renilla luciferase activity) compared with untreated or forskolin-treated cells. Forskolin increased the basal level of luciferase by 8.5-fold. **Po0.01 and *Po0.05 denote significant difference as compared with control conditions.
Functional selectivity at CB1 receptor B Bosier et al AP-1-driven luciferase activities. Also, as cannabinoid responses on CRE activity were more pronounced when the basal activity of AC was boosted, the effect of inhibitors on CRE-controlled transcription was evaluated in the presence of 1 mM forskolin. As expected, incubation of N1E-115 cells with H89 (10 mM) or KT5720 (5 mM) significantly reduced pCRE-Luc activity in the presence of forskolin (Table 1 ). In the same conditions, these PKA inhibitors completely abolished the modulation of pCRE-Luc activity caused by the cannabinoid agonists HU210 and CP55940.
The effects of MAPK kinase (MEK) and PI3K inhibitors were also investigated, as cannabinoids are known to regulate MAPK activity, possibly through PI3K activation. The MEK inhibitors U0126 (5 mM) and PD98059 (25 mM) were found to decrease the effect of forskolin on CRE-driven luciferase transcription. Similar reduction in CRE activity was observed in the absence of forskolin (74.5 ± 7.9 and 67.1 ± 2.3% relative to control cells, for U0126 and PD98059, Functional selectivity at CB1 receptor B Bosier et al respectively), suggesting that MAPKs are involved in the basal activity of CRE cis-enhancer elements. In contrast, these MEK inhibitors as well as the PI3K inhibitor wortmannin (0.2 mM) failed to reduce the effects of HU210 or CP55940. Finally, the PKC inhibitors chelerythrine (10 mM) or GF 109203X (0.25 mM), which were tested on the basis of the key role of this kinase in the modulation of AP-1-dependent transcriptional activity, were unable to influence the regulation of CRE activity by the cannabinoid agonists. In contrast to the responses obtained with the pCRE-Luc construct, the PKA inhibitors were without influence on the HU210-mediated regulation of AP-1-driven luciferase expression, whereas efficient blockade was obtained with the PKC inhibitors ( Table 2) . Compound Ro-31-6045, an analogue of GF 109203X, generally used as a negative control for inhibition of PKC activity, failed to influence the response to HU210, validating the specificity of the PKC inhibition. The failure of CP55940 to efficiently regulate AP-1 element was confirmed by our finding that none of the inhibitors tested here affected the response to this agonist. When used alone, inhibitors of MEK, PI3K or PKC were also found to affect the basal AP-1-mediated luciferase activity, suggesting that these kinases are involved in the constitutive AP-1-dependent transcriptional activity. Finally, neither MEK nor PI3K inhibitors appeared to influence the response to HU210.
Cannabinoid-mediated regulation of CRE and AP-1-dependent transcriptional activity is directed by G i/o proteins The role of G i/o -type G proteins in the modulation of gene transcription by cannabinoid agonists was examined by repeating the luciferase reporter assays in cells treated overnight with PTx (100 ng mL
À1
). In cells expressing either the pCRE-Luc or pAP-1-Luc constructs, the basal luciferase activities appeared to be substantially increased after treatment with PTx (17.4 and 12.4% relative to control, respectively), indicating that both transcription promoters were negatively influenced by a constitutive activation of G i/o -type G proteins.
As shown in Figure 2c , the inhibition of CRE-dependent luciferase activity induced by both HU210 and CP55940 in the presence of forskolin was abolished by PTx pretreatment (Figure 2c ). In contrast, when the assay was conducted in the absence of forskolin, the effect of cannabinoid agonists was switched from inhibition to induction of CRE-dependent transcription, and concentration-response curves revealed pEC 50 values of 6.64±0.26 and 6.67±0.27 for HU210 and CP55940, respectively (Figure 5a ). These data are consistent with the above-mentioned increase in cAMP levels in PTxtreated cells, demonstrating the dual coupling of the CB 1 receptor with the G i/o and G s -type G proteins.
Such reversal of the functional response to HU210 in PTxtreated cells was also observed when studying the modulation of luciferase under the control of AP-1. In these conditions, HU210 concentration-dependently stimulated luciferase activity with pEC 50 values of 7.66±0.38. More surprisingly, in this model of PTx-treated cells, CP55940 appeared to be effective in inducing AP-1-dependent transcription with a pEC 50 of 6.48±0.23 (Figure 5b ). Together, these data indicate that the regulation of AP-1 activity by cannabinoid agonists was also operating through the activation of members of the G i/o protein family.
Discussion and conclusions
The effects of cannabinoids on CNS activity are frequently related to the CB 1 receptor-mediated regulation of signalling cascades, controlling the release of other neurotransmitters. Beside these acute responses, several reports indicate that activation of the CB 1 receptor modulates transcription factors, including CREB, nuclear factor kappa B, nuclear factor-activated T cells and AP-1 (Ouyang et al., 1998; Herring et al., 2001) . In this study, using N1E-115 neuroblastoma cells that constitutively express CB 1 receptors, we report that the cannabinoid agonist HU210 concentrationdependently inhibits both CRE and AP-1-mediated transcriptional activities. In contrast, the unrelated cannabinoid agonist CP55940 fails to influence AP-1-controlled gene expression while efficiently regulating CRE activity. Furthermore, these responses are abolished and/or reversed in the Although the involvement of cannabinoid receptors was not definitely established, cAMP-dependent inhibition of CREB DNA binding after cannabinoid treatment has been previously demonstrated (Koh et al., 1997; Herring et al., 1998 Herring et al., , 2001 ). More recently, CB 1 receptor-mediated increase in CREB activation through ERK-dependent signalling was demonstrated in discrete regions of the rat brain after administration of cannabinoid agonists (Casu et al., 2005; Rubino et al., 2007) . Consistent with these studies, the use of a specific luciferase-based reporter assay revealed that both HU210 and CP55940 concentration-dependently inhibited CRE-dependent transcriptional activity through activation of CB 1 receptors, as indicated by the efficient blockade of the responses by SR141716A. The detection of this response was facilitated in cells exposed to forskolin, which boosts basal CRE-dependent transcriptional activity, suggesting that agonists were acting through inhibition of AC. This is consistent with our data showing a decreased cAMP accumulation in cells exposed to HU210 and CP55940. Indeed, the use of specific inhibitors confirmed that PKA was required for the forskolin-mediated induction of basal CRE activity. Accordingly, the PKA inhibitors totally abolished HU210 and CP55940-mediated regulation of CRE-dependent luciferase activity. Together, these data strongly support the general concept that agonists of CB 1 receptors influence gene transcription through inhibition of cAMP production and modulation of PKA activity. Nevertheless, concentration-response curves were characterized by a Hill coefficient o1, indicating that the regulation of CRE-dependent activity by the cannabinoid agonists could involve the combination of distinct but converging signalling pathways. Although cannabinoid receptors have been shown to regulate several types of G proteins, this complexity could merely involve different members of the family of G i/o proteins.
The AP-1 transcription factor is best characterized as a family of protein heterodimers encoded by defined immediate early genes, such as c-Fos and JunB. Therefore, AP-1 activity is dependent on the level of immediate early gene expression and the phosphorylation of the different subunits by PKC, ERK or c-Jun N-terminal kinase. As cannabinoid receptors are known to activate ERK1/2 and c-Jun N-terminal kinase, and regulate the expression of immediate early genes, the effects of cannabinoid agonists on AP-1-dependent transcriptional activity were characterized. Several studies have already shown cannabinoid-mediated regulations of AP-1 activity with inconsistent responses reflecting either increased or decreased in AP-1 DNA binding and/or AP-1-controlled transcription (Porcella et al., 1998; Faubert and Kaminski, 2000; Zhao et al., 2005; Giuliano et al., 2006) . Here, the direct measure of AP-1-dependent activity revealed a reduction of AP-1-mediated transcription in neuroblastoma cells, consecutively to HU210 stimulation. Accordingly, anandamide-mediated inhibition of AP-1 activation in a CB 1 receptor-and PKC-dependent mechanism was previously demonstrated (Maccarrone et al., 2003) . Likewise, HU210-mediated inhibition of AP-1-driven luciferase activity was efficiently inhibited by PKC inhibitors and antagonized using SR141716A. Although regulation of PKC-related pathways by cannabinoids remains poorly documented, several studies have already suggested a role of this kinase in cannabinoid receptor-mediated reduction of potassium currents (Hampson et al., 2000) and regulation of L-type voltage dependent calcium channels (Rubovitch et al., 2002) . In addition, demonstrations that CB 1 receptors may functionally interact with G q/11 -type G protein in response to (R)-( þ )-(2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)-1-naphthalenylmethanone mesylate (WIN55212-2) (Lauckner et al., 2005) and efficiently regulate PLC activity (Sugiura et al., 1996 (Sugiura et al., , 1997 Ho et al., 1999) are compelling indications for a CB 1 receptor-mediated regulation of PKC.
The absence of CP55940-mediated regulation of AP-1-dependent transcription clearly shows that distinct signalling cascades contribute to the modulation of CRE-and AP-1-dependent activities. In addition, these data support the concept of functional selectivity of agonists acting at the CB 1 receptor. Indeed, functional selectivity of receptor signalling is characterized by the ability of distinct ligands constructs. Cells were treated overnight with 100 ng mL À1 PTx. Thereafter, cells were exposed to increasing concentrations of HU210 or CP55940 and luciferase activity was monitored after 5 h. Results shown are mean values with s.e.mean from at least three separate experiments performed in triplicate and are given as the percentage of relative luciferase activity (firefly luciferase relative to Renilla luciferase activity) compared with control. *Po0.05 denotes significant difference as compared with control conditions. Functional selectivity at CB1 receptor B Bosier et al acting at a single G-protein-coupled receptor to differentially control intracellular signal transduction pathways. Thus, functionally selective ligands activate or inhibit multiple intracellular cascades with different efficacies or potencies . Such selectivity at the level of regulation of AP-1-dependent transcriptional activity by cannabinoid agonists is an unprecedented observation. Although the expression of the CB 1 receptor in this model of neuroblastoma cells remains poorly characterized, we have accumulated convincing pharmacological data showing that both agonists tested act on a single molecular target identified as the CB 1 receptor. It is noteworthy that both agonists promote reduction of CRE-dependent luciferase activity with similar potencies and decrease cAMP. This is also consistent with the data showing the possibility to competitively antagonize the HU210-mediated regulation of AP-1-dependent response by CP55940. Importantly, the pA 2 value determined for CP55940 in this competition assay is consistent with its published nanomolar affinity for the CB 1 receptor. The detection of signalling specificity with some drugs, as shown here for CP55940, could be purely related to their partial agonist profile. For these drugs, the density of receptors and the availability of defined signalling partners could influence the apparent efficacy in functional assays. However, to our knowledge, the vast majority of pharmacological studies have identified CP55940 as a full agonist of the CB 1 receptor. Although functional selectivity at G-protein-coupled receptors is extensively documented in the literature, little is known regarding the CB 1 receptor, and most available studies have been focused on coupling with different members of the G i/o protein family (Glass and Northup, 1999; Prather et al., 2000; Mukhopadhyay and Howlett, 2005) . Nevertheless, the ability of different CB 1 receptor agonists to differently activate G i/o or G s -dependent signalling pathways was described in recombinant systems (Bonhaus et al., 1998) . To our knowledge, this study provides the first evidence for functional selectivity at the native CB 1 receptor in a neural cell line, reflected by an agonist-selective response monitored at the transcriptional level. In a closely related study conducted in the same cell line, we recently reported the complex regulation of TH by CB 1 receptor agonists . Importantly, HU210 or CP55940 was shown to decrease or increase the expression of TH, respectively, raising the question of an agonistselective trafficking of CB 1 receptor signalling. Earlier studies demonstrated that AP-1 and CRE motifs present in the rat TH gene promoter were involved in the pharmacological modulation of transcription (Kim et al., 1993; Najimi et al., 2002; Lewis-Tuffin et al., 2004) . Therefore, identifying an agonist-dependent differential regulation of TH expression in a catecholamine-producing cell line, highlights the putative relevance of functional selectivity.
Inhibition or reversal of the responses to the cannabinoid agonists in PTx-treated cells suggests that both CRE and AP-1 activities are regulated through activation of G i/o -type G proteins, in accordance with the documented predominant coupling of the CB 1 receptor. The unexpected reduction of basal cAMP level observed after overnight treatment with PTx could reveal some influence of this toxin on the metabolism or proliferation of N1E-115 cells. However, forskolin was found to induce equivalent increases in cAMP accumulation in cells with or without exposure to PTx (725.08±55.97 and 728.58±41.15% stimulation, relative to control), suggesting that the pharmacological modulation of AC and associated signalling were not affected. Taking advantage of an internal control plasmid (encoding for Functional selectivity at CB1 receptor B Bosier et al Renilla luciferase) that allowed us to normalize for cell density, an enhanced basal luciferase activity in PTx-treated cells was detected, confirming the stimulation of both CRE and AP-1-dependent transcription by some constitutive activation of G i/o -type G proteins in N1E-115 cells. In addition, the inverse agonist, SR141716A, also increased luciferase activity (not shown), indicating that a constitutive coupling of the CB 1 receptor participates in the activation of CRE and AP-1 in the absence of agonist. The putative interaction of the CB 1 receptor with several isoforms of G i/o proteins could certainly hold clues for the diversity in intracellular signalling triggered by cannabinoid ligands and explain the results observed with HU210 and CP55940 (Figure 6 ). On the other hand, although the aim of the study was not to examine the diversity of couplings with different types of G proteins, our data suggest that in the absence of functional G i/o protein, the CB 1 receptor may operate atypical coupling with other G proteins. Indeed, increased cAMP accumulation and stimulation of CREdriven luciferase activity in PTx-treated cells indicate that CB 1 receptors also exert a positive influence on AC through a putative coupling with G s -type G protein. Besides, considering the consequence of PTx pretreatment on HU210 and CP55940-mediated regulation of AP-1 activity, the possibility of coupling with members of the G q/11 proteins family cannot be excluded.
In conclusion, the present results indicate that two cannabinoid ligands, commonly used as reference agonists at the CB 1 receptor, may differentially influence gene transcription through distinct controls on AP-1 cis-enhancer DNA element. Supporting the concept of functional selectivity, these data suggest that the choice of appropriate ligands acting on a given receptor should help to selectively modulate defined cellular responses. In addition, the present observations clearly indicate that ligands, with similar pharmacodynamic properties and eliciting similar regulation of classical immediate effectors, may trigger divergent delayed responses. This should encourage the systematic study of a wide variety of early and late responses to drugs to better define their therapeutic potential or explain the differences in their clinical profiles.
